248 related articles for article (PubMed ID: 30024982)
1. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.
Zhang R; Xi X; Wang C; Pan Y; Ge C; Zhang L; Zhang S; Liu H
PLoS One; 2018; 13(7):e0201025. PubMed ID: 30024982
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy.
Johnson BJ; Ress SR; Willcox P; Pati BP; Lorgat F; Stead P; Saha R; Lukey P; Laochumroonvorapong P; Corral L
Cytokines Mol Ther; 1995 Sep; 1(3):185-96. PubMed ID: 9384675
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients.
Johnson BJ; Estrada I; Shen Z; Ress S; Willcox P; Colston MJ; Kaplan G
Infect Immun; 1998 Jun; 66(6):2426-33. PubMed ID: 9596698
[TBL] [Abstract][Full Text] [Related]
4. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.
Johnson BJ; Bekker LG; Rickman R; Brown S; Lesser M; Ress S; Willcox P; Steyn L; Kaplan G
Tuber Lung Dis; 1997; 78(3-4):195-203. PubMed ID: 9713652
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Adjunctive Recombinant Human Interleukin-2 for Patients with Pulmonary Tuberculosis: A Meta-Analysis.
Sheng L; Li X; Weng F; Wu S; Chen Y; Lou L
J Trop Med; 2022; 2022():5071816. PubMed ID: 36467716
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of vitamin D supplementation on the outcome of pulmonary tuberculosis treatment in adults: a meta-analysis of randomized controlled trials.
Zhang J; Chen C; Yang J
Chin Med J (Engl); 2019 Dec; 132(24):2950-2959. PubMed ID: 31833904
[TBL] [Abstract][Full Text] [Related]
7. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia.
Shibabaw A; Gelaw B; Wang SH; Tessema B
PLoS One; 2018; 13(6):e0198080. PubMed ID: 29944658
[TBL] [Abstract][Full Text] [Related]
8. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
Wang M; Guan X; Chi Y; Robinson N; Liu JP
Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis.
Huang CY; Hsieh WY
Hum Vaccin Immunother; 2017 Sep; 13(9):1960-1971. PubMed ID: 28604170
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study.
Shu CC; Wang JT; Lee CH; Wang JY; Lee LN; Yu CJ
BMC Infect Dis; 2010 Mar; 10():48. PubMed ID: 20205743
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.
Jolliffe DA; Ganmaa D; Wejse C; Raqib R; Haq MA; Salahuddin N; Daley PK; Ralph AP; Ziegler TR; Martineau AR
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30728208
[TBL] [Abstract][Full Text] [Related]
13. The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Wagnew F; Alene KA; Kelly M; Gray D
Int J Infect Dis; 2023 Feb; 127():93-105. PubMed ID: 36481489
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis.
Calderwood CJ; Wilson JP; Fielding KL; Harris RC; Karat AS; Mansukhani R; Falconer J; Bergstrom M; Johnson SM; McCreesh N; Monk EJM; Odayar J; Scott PJ; Stokes SA; Theodorou H; Moore DAJ
PLoS Med; 2021 Apr; 18(4):e1003566. PubMed ID: 33901173
[TBL] [Abstract][Full Text] [Related]
15. Outcome correlation of smear-positivity for acid-fast bacilli at the fifth month of treatment in non-multidrug-resistant TB.
Chien JY; Chen YT; Shu CC; Lee JJ; Wang JY; Yu CJ; Yang PC
Chest; 2013 Jun; 143(6):1725-1732. PubMed ID: 23288018
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
Alene KA; Viney K; Yi H; McBryde ES; Yang K; Bai L; Gray DJ; Xu Z; Clements ACA
PLoS One; 2018; 13(5):e0197880. PubMed ID: 29791488
[TBL] [Abstract][Full Text] [Related]
17. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
Putri FA; Burhan E; Nawas A; Soepandi PZ; Sutoyo DK; Agustin H; Isbaniah F; Dowdy DW
Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.
Condos R; Rom WN; Schluger NW
Lancet; 1997 May; 349(9064):1513-5. PubMed ID: 9167461
[TBL] [Abstract][Full Text] [Related]
19. Sputum conversion at the end of intensive phase of Category-1 regimen in the treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection: An analysis of risk factors.
Banu Rekha VV; Balasubramanian R; Swaminathan S; Ramachandran R; Rahman F; Sundaram V; Thyagarajan K; Selvakumar N; Adhilakshmi AR; Iliayas S; Narayanan PR
Indian J Med Res; 2007 Nov; 126(5):452-8. PubMed ID: 18160750
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for tuberculosis smear non-conversion in Eden district, Western Cape, South Africa, 2007-2013: a retrospective cohort study.
Mlotshwa M; Abraham N; Beery M; Williams S; Smit S; Uys M; Reddy C; Medina-Marino A
BMC Infect Dis; 2016 Aug; 16():365. PubMed ID: 27484399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
